using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
Name: Atezolizumab Injection; bevacizumab Injection
Description: The percentage of patients with radiologically complete or partial response as determined by the investigator according to RECIST version 1.1.
Measure: Objective response rate (ORR) Time: 9 MONTHSDescription: PFS is measured from the date of study enrollment to radiographically documented progression according to RECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow-up will be censored at the date of their last radiographic assessment.
Measure: Progression-free Survival (PFS) Time: about 9 monthsAllocation: N/A
Single Group Assignment
There are 4 SNPs
EGFR activating mutations include exon19 deletion, L858R, G719X, L861Q, or S768I. --- L858R ---
EGFR activating mutations include exon19 deletion, L858R, G719X, L861Q, or S768I. --- L858R --- --- L861Q ---
EGFR activating mutations include exon19 deletion, L858R, G719X, L861Q, or S768I. --- L858R --- --- L861Q --- --- S768I ---
The treatment-free interval of neoadjuvant or adjuvant platinum-based chemotherapy should be more than 6 months before study enrollment is allowed - Previous exposure to VEGF inhibitor for anti-cancer treatment - Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other immuno-regulatory receptors or mechanisms - Patients carries EGFR genotype T790M or exon20 insertion should be excluded. --- T790M ---